Orally active growth hormone secretagogues: State of the art and clinical perspectives

Annals of Medicine

Volumn 30, Issue 2, 1998, Pages 159-168

  Ghigo, Ezio ^a,b   Arvat, Emanuela ^a   Camanni, Franco ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b MOLINETTE HOSPITAL   (Italy)

Author keywords

Growth hormone; Growth hormone insufficiency; Growth hormone secretagogues; Insulin like growth factor I

Indexed keywords

GROWTH HORMONE; GROWTH HORMONE DERIVATIVE; GROWTH HORMONE RECEPTOR; GROWTH HORMONE RELEASING FACTOR; HEXARELIN; HISTIDYL DEXTRO TRYPTOPHYLALANYLTRYPTOPHYL DEXTRO PHENYLALANYLLYSINAMIDE; LIGAND; SOMATOMEDIN C;

ACROMEGALY; ANOREXIA NERVOSA; ARTICLE; CRITICAL ILLNESS; CUSHING SYNDROME; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPERTHYROIDISM; HYPOPHYSIS; HYPOTHALAMUS; HYPOTHYROIDISM; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031979460     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899808999399     Document Type: Article

References (21)

1. Bowers CY, Chang J, Momany F, Folkers K. Effects of the enkephalins and enkephalin analogs on release of pituitary hormones in vitro. In: Macintyne I, ed. Molecular Endocrinology. Amsterdam: Elsevier; 1977: 287-92.
2. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 1984; 114: 1531-6.
3. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu BB, Walker RF, eds. Growth Hormone II, Basic and Clinical Aspects. New York: Springer-Verlag; 1993: 203-22.
4. Deghenghi R, Bontignon F, Luoni M, Grilli R, Guidi M, Locatelli V. Small peptides as potent releasers of growth hormone. J Pediatr Endocrinol Metab 1995; 8: 311-3.
5. Korbonits M, Grossman AB. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 1996; 6: 43-9.
6. Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. Eur J Endocrinol 1997; 136: 445-60.
7. Jacks T, Smith R, Judith F, et al. MK-0677, a potent novel, orally-active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996; 137: 5284-9.
8. Copinschi G, Van Onderbergen A, L'Hermite-Baleriaux M, et al. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996; 81: 2776-82.
9. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-57.
10. Ghigo E, Arvat E, Gianotti L, et al. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693-8.
11. Jacks T, Hickey G, Judith F, et al. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 1994; 143: 399-406.
12. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70: 975-82.
13. Gertz BJ, Barrett JS, Eisenhandler R, et al. Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab 1993; 77: 1393-7.
14. Aloi JA, Gertz BJ, Hartman ML, et al. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994; 79: 943-9.
15. Korbonits M, Trainer PJ, Besser GM. The effect of an opiate antagonist on the hormonal changes induced by Hexarelin. Clin Endocrinol 1995; 43: 365-71.
16. Locke W, Kirgis HD, Bowers CY, Abdo AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci 1995; 56: 1347-52.
17. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995; 61: 584-9.
18. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-7.
19. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989; 28: 1139-44.
20. Muccioli G, Ghé C, Ghigo MC, et al. GHRP receptors in pituitary, central nervous system and peripheral human tissues. J Endocrinol Invest 1997; 20 (Suppl 4): 52.
21. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller EE, Berti F. Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharmacol 1997; 334: 201-7.